Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41276502.
- Also identified by DOI 10.1038/s41467-025-66296-5 and PMC identifier 12749807.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
MASLD (metabolic-associated steatotic liver disease) and MASH (steatohepatitis) are closely associated with hepatic IR (insulin resistance) and T2D. Regardless, insulin-stimulated hepatic lipogenesis is considered essential for MASLD development, as mouse models of complete hepatic IR become diabetic without MASLD when fed high-fat diets. Challenging this notion, we found that male LDKO mice lacking hepatic insulin receptor substrates acutely developed MASLD if fed a fructose-enriched "MASH diet" (GAN) or high-fructose diet. Fructose potentiated hepatic re-esterification of abundant circulating fatty acids in LDKO mice, evidenced by excess <sup>13</sup>C incorporation into the glycerol backbone-but not fatty acid chains-of hepatic triacylglyceride after gavage with [U<sup>13</sup>C]fructose. Suppressing adipose lipolysis in LDKO mice by inactivating hepatic Fst (Follistatin) prevented acute MASLD, whereas over-expressing Fst in wild-type mouse liver accelerated GAN-promoted MASLD/MASH. Compatibly, higher serum FST levels among Tübingen Diabetes Family Study participants clustered with increased adipose IR and greater hepatic triacylglyceride accumulation.
Medical subject headings
- Insulin Resistance
- Fructose
- Liver
- Follistatin
- Fatty Liver